A new study by Castle Biosciences reveals that more than 55% of atopic dermatitis (AD) patients using targeted systemic therapies modify their treatment due to lack of efficacy. The study highlights strong patient interest in molecular testing, with 94% of those open to new therapies wanting tests to guide treatment choices. Castle's AdvanceAD-Tx test offers personalized treatment guidance by analyzing gene expression to identify the best systemic therapy based on individual disease biology. This approach aims to improve treatment outcomes and speed relief for moderate-to-severe AD patients.
The new study on molecular guidance in atopic dermatitis treatment highlights a significant clinical need. For readers following the health sector, here is Pluang's market snapshot as of Sep 25, 2026 03:02 WIB: Out of 100 priced US health-sector stocks, 33 rose and 67 fell. Notable movers include TXG (10X Genomics Inc) at USD 84.78 with a 12.11% increase and a typical hold time of 94 days, ILMN (Illumina, Inc.) at USD 273.73 up 7.19% with a hold time of 85 days, and MRNA (Moderna, Inc.) at USD 194.82 rising 6.98% but with 87% sell order activity.
Costco reported a strong Q4 earnings per share (EPS) of $6.75, surpassing analyst expectations of $6.54, helped by tariff refunds. Although quarterly revenue of $93.87 billion slightly missed the $94.97 billion forecast, net sales rose 11.2% year-ove...
Vistry Group reported a significant first-half pre-tax loss of £661.3 million, driven by a £475 million goodwill impairment and increased building safety costs. Revenue fell to £1.42 billion, and operational performance weakened with fewer home compl...
Vail Resorts is set to report its Q3 2026 earnings on September 28, with analysts forecasting a loss per share around -$5.30 and revenue near $271 million, indicating flat performance year-over-year. The company’s financial health shows a high Debt-t...
REGENXBIO announced positive 3-year results from its Phase II ALTITUDE trial of surabgene lomparvovec (sura-vec) for non-proliferative diabetic retinopathy (NPDR). A single in-office gene therapy dose led to over 60% of participants achieving more th...
Ethereum (ETH) has printed its first higher high since its August 2025 peak, breaking a year-long pattern of lower highs. It surpassed the $2,438 resistance level, which has now turned into support, signaling a more bullish weekly structure. However,...
